ERBB2 and breast cancer: Similarly, the PALBOSPAIN study, a retrospective, multi-center, observational, study evaluating real-world patterns and outcomes with first-line palbociclib in men and women with advanced HR+/HER2– breast cancer in Spain, reported a median real-world PFS and OS of 24 and 42 months, respectively [18].